Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/116223
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Watz, Henrik | - |
dc.contributor.author | Troosters, Thierry | - |
dc.contributor.author | Beeh, Kai M. | - |
dc.contributor.author | García Aymerich, Judith | - |
dc.contributor.author | Paggiaro, Pierluigi | - |
dc.contributor.author | Molins, Eduard | - |
dc.contributor.author | Notari, Massimo | - |
dc.contributor.author | Zapata, Antonio | - |
dc.contributor.author | Jarreta, Diana | - |
dc.contributor.author | Garcia Gil, Esther | - |
dc.date.accessioned | 2017-10-05T11:34:41Z | - |
dc.date.available | 2017-10-05T11:34:41Z | - |
dc.date.issued | 2017-08-24 | - |
dc.identifier.issn | 1176-9106 | - |
dc.identifier.uri | http://hdl.handle.net/2445/116223 | - |
dc.description.abstract | The Phase IV, 8-week, randomized, double-blind, placebo-controlled ACTIVATE study (NCT02424344) evaluated the effect of aclidinium/formoterol (AB/FF) 400/12 mug twice daily on lung hyperinflation, exercise capacity, and physical activity in patients with moderate-to-severe COPD. Patients received AB/FF (n=134) or placebo (n=133) (1:1) via the Genuair/Pressair(R) dry powder inhaler for 8 weeks. From Weeks 5 to 8, all patients participated in behavioral intervention (BI; daily messages providing step goals). The primary end point was trough functional residual capacity (FRC) at Week 4. Exercise endurance time and physical activity were assessed at Week 4 (pharmacotherapy only) and at Week 8 (8 weeks of pharmacotherapy plus 4 weeks of BI). Other end points included post-dose FRC, residual volume, and inspiratory capacity (IC) at rest and during exercise. After 4 weeks, trough FRC improved with AB/FF versus placebo but did not reach significance (125 mL; P=0.0690). However, post-dose FRC, residual volume, and IC at rest improved significantly with AB/FF at Week 4 versus placebo (all P<0.0001). AB/FF significantly improved exercise endurance time and IC at isotime versus placebo at Week 4 (P<0.01 and P<0.0001, respectively) and Week 8 (P<0.05 and P<0.0001, respectively). AB/FF achieved higher step counts (P<0.01) with fewer inactive patients (P<0.0001) at Week 4 versus placebo. Following BI, AB/FF maintained improvements in physical activity at Week 8 and nonsignificant improvements were observed with placebo. AB/FF 400/12 mug demonstrated improvements in lung hyperinflation, exercise capacity, and physical activity versus placebo that were maintained following the addition of BI. A 4-week period of BI might be too short to augment the improvements of physical activity observed with AB/FF. | - |
dc.format.extent | 14 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Dove Press | - |
dc.relation.isformatof | Reproducció del document publicat a: http://dx.doi.org/10.2147/COPD.S143488 | - |
dc.relation.ispartof | International Journal of Chronic Obstructive Pulmonary Disease, 2017, vol. 12, num. , p. 2545-2558 | - |
dc.relation.uri | http://dx.doi.org/10.2147/COPD.S143488 | - |
dc.rights | cc by-nc (c) Watz et al., 2017 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/3.0/es | - |
dc.source | Articles publicats en revistes (ISGlobal) | - |
dc.subject.classification | Malalties pulmonars obstructives cròniques | - |
dc.subject.classification | Condició física | - |
dc.subject.other | Chronic obstructive pulmonary diseases | - |
dc.subject.other | Physical fitness | - |
dc.title | ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2017-10-04T18:00:04Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 28883722 | - |
Appears in Collections: | Articles publicats en revistes (ISGlobal) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
watz2017_2685.pdf | 2.44 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License